ARCHIVES

An old drug’s 21st century makeover begins with 84-fold price increase. Price hike of procarbazine astonishes brain tumor specialists.

This article is from The Cancer Letter archive.

Vol. 31 No. 19 | May 13, 2005

Download PDF Visit The Full Archive

Related Articles

Ibrutinib Demonstrates 71% ORR In Phase Ib/II CLL and SLL Study

July 26, 2013

Reauthorization Battle Warms Up; Administration, But Not Wyngaarden, May OK Cancer Act Renewal

March 18, 1988

In Brief: Maguire Wants Five Environmental Experts In Addition To Those On The Board

February 16, 1979

Researchers Uncover Tumors Sensitive to Chemotherapy

January 25, 2013

Clinical Oncology Program Has Top Priority Fink Says

February 9, 1979

ASPO Hears Proposals For Economic Attacks On Tobacco Industry

April 7, 1989